Skip to main content
AAN.com
Articles
September 19, 2012

Blood pressure changes in acute ischemic stroke and outcome with respect to stroke etiology

October 2, 2012 issue
79 (14) 1440-1448

Abstract

Objective:

Previous research suggested that proper blood pressure (BP) management in acute stroke may need to take into account the underlying etiology.

Methods:

All patients with acute ischemic stroke registered in the ASTRAL registry between 2003 and 2009 were analyzed. Unfavorable outcome was defined as modified Rankin Scale score >2. A local polynomial surface algorithm was used to assess the effect of baseline and 24- to 48-hour systolic BP (SBP) and mean arterial pressure (MAP) on outcome in patients with lacunar, atherosclerotic, and cardioembolic stroke.

Results:

A total of 791 patients were included in the analysis. For lacunar and atherosclerotic strokes, there was no difference in the predicted probability of unfavorable outcome between patients with an admission BP of <140 mm Hg, 140–160 mm Hg, or >160 mm Hg (15.3 vs 12.1% vs 20.8%, respectively, for lacunar, p = 015; 41.0% vs 41.5% vs 45.5%, respectively, for atherosclerotic, p = 075), or between patients with BP increase vs decrease at 24–48 hours (18.7% vs 18.0%, respectively, for lacunar, p = 0.84; 43.4% vs 43.6%, respectively, for atherosclerotic, p = 0.88). For cardioembolic strokes, increase of BP at 24–48 hours was associated with higher probability of unfavorable outcome compared to BP reduction (53.4% vs 42.2%, respectively, p = 0.037). Also, the predicted probability of unfavorable outcome was significantly different between patients with an admission BP of <140 mm Hg, 140–160 mm Hg, and >160 mm Hg (34.8% vs 42.3% vs 52.4%, respectively, p < 0.01).

Conclusions:

This study provides evidence to support that BP management in acute stroke may have to be tailored with respect to the underlying etiopathogenetic mechanism.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (figure_e-1.pptx)

REFERENCES

1.
Spence JD, Del Maestro RF. Hypertension in acute ischemic strokes: treat. Arch Neurol 1985;42:1000–1002.
2.
Yatsu FM, Zivin J. Hypertension in acute ischemic strokes: not to treat. Arch Neurol 1985;42:999–1000.
3.
Ntaios G, Bath P, Michel P. Blood pressure treatment in acute ischemic stroke: a review of studies and recommendations. Curr Opin Neurol 2010;23:46–52.
4.
Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K, Takishita S. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens 2005;23:1217–1223.
5.
Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002;33:1315–1320.
6.
Vemmos KN, Tsivgoulis G, Spengos K, et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004;255:257–265.
7.
Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al. Effects of clinical and laboratory variables and of pretreatment with cardiovascular drugs in acute ischaemic stroke: a retrospective chart review from the GIFA study. Int J Cardiol 2011;151:318–322.
8.
Geeganage C, Bath PM. Vasoactive drugs for acute stroke. Cochrane Database Syst Rev 2010;CD002839.
9.
Tuttolomondo A, Di SR, Di RD, et al. Arterial stiffness indexes in acute ischemic stroke: relationship with stroke subtype. Atherosclerosis 2010;211:187–194.
10.
Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients: the modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 1976;53:720–727.
11.
England TJ, Bath PM, Sare GM, et al. Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. Stroke 2010;41:2834–2839.
12.
Ntaios G, Lambrou D, Michel P. Blood pressure change and outcome in acute ischemic stroke: the impact of baseline values, previous hypertensive disease and previous antihypertensive treatment. J Hypertens 2011;29:1583–1589.
13.
Vemmos KN, Tsivgoulis G, Spengos K, et al. Blood pressure course in acute ischaemic stroke in relation to stroke subtype. Blood Press Monit 2004;9:107–114.
14.
Michel P, Odier C, Rutgers M, et al. The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. Stroke 2010;41:2491–2498.
15.
Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
16.
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
17.
Rordorf G, Cramer SC, Efird JT, Schwamm LH, Buonanno F, Koroshetz WJ. Pharmacological elevation of blood pressure in acute stroke: clinical effects and safety. Stroke 1997;28:2133–2138.
18.
Spence JD, Sibbald WJ, Cape RD. Pseudohypertension in the elderly. Clin Sci Mol Med Suppl 1978;4:399s–402s.
19.
Spence JD. Pseudo-hypertension in the elderly: still hazy, after all these years. J Hum Hypertens 1997;11:621–623.
20.
Spence JD. Pseudohypertension. In:, Laragh JH, Brenner BM eds. Hypertension, Diagnosis and Management. New York NY: Raven Press; 1995:1929–1937.
21.
Spence JD. Treating hypertension in acute ischemic stroke. Hypertension 2009;54:702–703.
22.
Vemmos KN, Tsivgoulis G, Spengos K, et al. Association between 24-h blood pressure monitoring variables and brain oedema in patients with hyperacute stroke. J Hypertens 2003;21:2167–2173.
23.
Bogousslavsky J, Regli F, Besson G, Pinho e Melo, Nater B. Early clinical diagnosis of stroke subtype. Cerebrovasc Dis 1993;3:39–44.
24.
van WC, Hart RG. Leave 'em alone: why continuous variables should be analyzed as such. Neuroepidemiology 2008;30:138–139.
25.
Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699–1703.
26.
Delgado-Mederos R, Ribo M, Rovira A, et al. Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology 2008;71:552–558.

Information & Authors

Information

Published In

Neurology®
Volume 79Number 14October 2, 2012
Pages: 1440-1448
PubMed: 22993273

Publication History

Received: November 18, 2011
Accepted: May 22, 2012
Published online: September 19, 2012
Published in print: October 2, 2012

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Authors

Affiliations & Disclosures

G. Ntaios, MD
From the Department of Medicine (G.N.), University of Thessaly, Larissa, Greece; and Neurology Service (G.N., D.L., P.M.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
D. Lambrou, PhD
From the Department of Medicine (G.N.), University of Thessaly, Larissa, Greece; and Neurology Service (G.N., D.L., P.M.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
National Regulatory Authority for Telecoms & Post Oppfices
Consultancies:
1.
CHUV
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
P. Michel, MD
From the Department of Medicine (G.N.), University of Thessaly, Larissa, Greece; and Neurology Service (G.N., D.L., P.M.), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
Bayer, Boehringer-Ingelheim
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Bayer, Lundbeck
Editorial Boards:
1.
International Journal of Stroke.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Servier, Lundbeck
Speakers’ Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Lundbeck
Research Support, Government Entities:
1.
Swiss National Science Foundation
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Swiss Cardiology Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Study funding: G.N. received scholarships from the European Stroke Organization and the Hellenic Atherosclerosis Society. The study was also supported by grants from the Swiss Cardiology Foundation and Cardiomet-CHUV.
Correspondence & reprint requests to Dr. Ntaios: [email protected].

Author Contributions

Dr. Ntaios: study concept and design, analysis and interpretation, preparation of the manuscript. Dr. Lambrou: analysis and interpretation, critical revision of the manuscript for important intellectual content. Dr. Michel: study concept and design, acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content, study supervision.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Pathogenetic scenarios of the development of brain ischemia and the main elements of the ischemic cascade, Translational Medicine, 11, 1, (87-102), (2024).https://doi.org/10.18705/2311-4495-2024-11-1-87-102
    Crossref
  2. Prognostic significance of 24‐h blood pressure and variability indices in the outcome of acute ischaemic stroke, Internal Medicine Journal, 53, 7, (1137-1146), (2022).https://doi.org/10.1111/imj.15834
    Crossref
  3. Time of blood pressure in target range in acute ischemic stroke, Journal of Hypertension, 41, 2, (303-309), (2022).https://doi.org/10.1097/HJH.0000000000003331
    Crossref
  4. Relationship between blood pressure and outcome changes over time in acute ischemic stroke, Neurology, 95, 10, (e1362-e1371), (2020)./doi/10.1212/WNL.0000000000010203
    Abstract
  5. Intensive versus guideline‐recommended blood pressure reduction in acute lacunar stroke with intravenous thrombolysis therapy: The ENCHANTED trial, European Journal of Neurology, 28, 3, (783-793), (2020).https://doi.org/10.1111/ene.14598
    Crossref
  6. Serum immunoglobulin G antibody titer to Fusobacterium nucleatum is associated with unfavorable outcome after stroke , Clinical and Experimental Immunology, 200, 3, (302-309), (2020).https://doi.org/10.1111/cei.13430
    Crossref
  7. Association of Elevated Blood Pressure Levels with Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: A Systematic Review and Meta-Analysis, Journal of Stroke, 21, 1, (78-90), (2019).https://doi.org/10.5853/jos.2018.02369
    Crossref
  8. Blood pressure fluctuation pattern and stroke outcomes in acute ischemic stroke, Hypertension Research, 42, 11, (1776-1782), (2019).https://doi.org/10.1038/s41440-019-0292-9
    Crossref
  9. In-hospital dynamics of glucose, blood pressure and temperature predict outcome in patients with acute ischaemic stroke, European Stroke Journal, 3, 2, (174-184), (2018).https://doi.org/10.1177/2396987318765824
    Crossref
  10. Blood pressure in acute ischemic stroke, Journal of Hypertension, 36, 6, (1212-1221), (2018).https://doi.org/10.1097/HJH.0000000000001704
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share